73 related articles for article (PubMed ID: 11410480)
1. The battle between tumor suppressors: is gene therapy using p16(INK4a) more efficacious than p53 for treatment of ovarian carcinoma?
Murphy ME
Clin Cancer Res; 2001 Jun; 7(6):1487-9. PubMed ID: 11410480
[No Abstract] [Full Text] [Related]
2. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
Ramirez PT; Gershenson DM; Tortolero-Luna G; Ramondetta LM; Fightmaster D; Wharton JT; Wolf JK
Gynecol Oncol; 2001 Dec; 83(3):543-8. PubMed ID: 11733969
[TBL] [Abstract][Full Text] [Related]
3. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
Havrilesky LJ; Alvarez AA; Whitaker RS; Marks JR; Berchuck A
Gynecol Oncol; 2001 Dec; 83(3):491-500. PubMed ID: 11733961
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.
Peng CY; Chen TC; Hung SP; Chen MF; Yeh CT; Tsai SL; Chu CM; Liaw YF
Anticancer Res; 2002; 22(2B):1265-71. PubMed ID: 12168936
[TBL] [Abstract][Full Text] [Related]
5. [Gene therapy with tumor suppressor gene p53 and(or) p16 on the nude mice models of NSCLC in vivo].
Wu W; Zhang X; Qi X
Zhonghua Jie He He Hu Xi Za Zhi; 2000 Jul; 23(7):403-5. PubMed ID: 11778504
[TBL] [Abstract][Full Text] [Related]
6. Low prevalence of p53, p16(INK4a) and Ha-ras tumour-specific mutations in low-graded actinic keratosis.
Nindl I; Gottschling M; Krawtchenko N; Lehmann MD; Röwert-Huber J; Eberle J; Stockfleth E; Forschner T
Br J Dermatol; 2007 May; 156 Suppl 3():34-9. PubMed ID: 17488404
[TBL] [Abstract][Full Text] [Related]
7. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Aug; 441(2):133-42. PubMed ID: 12189502
[TBL] [Abstract][Full Text] [Related]
8. [Combination of adenovirus p16(INK4A) gene therapy and ionizing radiation for laryngeal squamous cell carcinoma].
Fu YJ; Liu SX; Xian JM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Mar; 35(2):209-11. PubMed ID: 15071918
[TBL] [Abstract][Full Text] [Related]
9. Co-transfection of p16(INK4a) and p53 genes into the K562 cell line inhibits cell proliferation.
Rui HB; Su JZ
Haematologica; 2002 Feb; 87(2):136-42. PubMed ID: 11836163
[TBL] [Abstract][Full Text] [Related]
10. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.
Wang Y; Zhang Z; Kastens E; Lubet RA; You M
Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609
[TBL] [Abstract][Full Text] [Related]
11. Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer.
DeInnocentes P; Agarwal P; Bird RC
J Cell Biochem; 2009 Feb; 106(3):491-505. PubMed ID: 19130492
[TBL] [Abstract][Full Text] [Related]
12. Differential roles of p16INK4A and p14ARF genes in prognosis of oral carcinoma.
Sailasree R; Abhilash A; Sathyan KM; Nalinakumari KR; Thomas S; Kannan S
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):414-20. PubMed ID: 18268126
[TBL] [Abstract][Full Text] [Related]
13. Alterations of the INK4a-ARF gene locus in pleomorphic adenoma of the parotid gland.
Weber A; Langhanki L; Schütz A; Wittekind C; Bootz F; Tannapfel A
J Pathol; 2002 Nov; 198(3):326-34. PubMed ID: 12375265
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of tumor suppressor p53, p21, and p16 gene therapy effects on glioblastoma tumorigenicity in situ.
Wang TJ; Huang MS; Hong CY; Tse V; Silverberg GD; Hsiao M
Biochem Biophys Res Commun; 2001 Sep; 287(1):173-80. PubMed ID: 11549271
[TBL] [Abstract][Full Text] [Related]
15. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
16. p16(INK4a) and p53 deficiency cooperate in tumorigenesis.
Sharpless NE; Alson S; Chan S; Silver DP; Castrillon DH; DePinho RA
Cancer Res; 2002 May; 62(10):2761-5. PubMed ID: 12019151
[TBL] [Abstract][Full Text] [Related]
17. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.
Sharpless NE; Ramsey MR; Balasubramanian P; Castrillon DH; DePinho RA
Oncogene; 2004 Jan; 23(2):379-85. PubMed ID: 14724566
[TBL] [Abstract][Full Text] [Related]
18. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.
D'Amico M; Wu K; Fu M; Rao M; Albanese C; Russell RG; Lian H; Bregman D; White MA; Pestell RG
Cancer Res; 2004 Jun; 64(12):4122-30. PubMed ID: 15205322
[TBL] [Abstract][Full Text] [Related]
19. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.
Oda Y; Yamamoto H; Takahira T; Kobayashi C; Kawaguchi K; Tateishi N; Nozuka Y; Tamiya S; Tanaka K; Matsuda S; Yokoyama R; Iwamoto Y; Tsuneyoshi M
J Pathol; 2005 Dec; 207(4):410-21. PubMed ID: 16177957
[TBL] [Abstract][Full Text] [Related]
20. Alterations in the p16(INK4a) and p53 tumor suppressor genes of hTERT-immortalized human fibroblasts.
Noble JR; Zhong ZH; Neumann AA; Melki JR; Clark SJ; Reddel RR
Oncogene; 2004 Apr; 23(17):3116-21. PubMed ID: 14743210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
